{"analyses":[{"ciLowerLimit":"0.88","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.08","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 6","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"0.97"},{"ciLowerLimit":"0.93","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.16","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 6","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0).","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.03"},{"ciLowerLimit":"0.95","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.19","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 6","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0).","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.06"},{"ciLowerLimit":"0.90","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.11","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 11","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0).","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.00"},{"ciLowerLimit":"0.95","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.20","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 11","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0).","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.07"},{"ciLowerLimit":"0.95","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.20","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 11","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0).","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.07"},{"ciLowerLimit":"0.86","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.06","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 16","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0).","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"0.96"},{"ciLowerLimit":"0.90","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.12","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 16","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.00"},{"ciLowerLimit":"0.94","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.17","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 16","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.05"},{"ciLowerLimit":"0.89","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.14","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 18","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.00"},{"ciLowerLimit":"0.98","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.26","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 18","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.11"},{"ciLowerLimit":"0.97","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.26","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 18","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.11"},{"ciLowerLimit":"0.89","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.13","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 31","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.00"},{"ciLowerLimit":"0.91","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.16","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 31","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.02"},{"ciLowerLimit":"0.90","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.15","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 31","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.02"},{"ciLowerLimit":"0.94","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.16","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 33","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.05"},{"ciLowerLimit":"0.94","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.17","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 33","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.05"},{"ciLowerLimit":"0.90","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.12","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 33","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.01"},{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.95","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 45","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"0.84"},{"ciLowerLimit":"0.91","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.18","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 45","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.04"},{"ciLowerLimit":"1.08","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.42","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 45","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.24"},{"ciLowerLimit":"0.83","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.03","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 52","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"0.92"},{"ciLowerLimit":"0.85","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.07","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 52","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"0.95"},{"ciLowerLimit":"0.92","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.16","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 52","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.03"},{"ciLowerLimit":"0.86","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.06","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 58","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"0.95"},{"ciLowerLimit":"0.96","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.20","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 58","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.07"},{"ciLowerLimit":"1.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.26","estimateComment":"GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 58","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)","nonInferiorityType":"EQUIVALENCE","paramType":"GMT ratio","paramValue":"1.12"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1588.7","upperLimit":"1852.2","value":"1715.4"},{"groupId":"OG001","lowerLimit":"1635.4","upperLimit":"1901.3","value":"1763.3"},{"groupId":"OG002","lowerLimit":"1540.3","upperLimit":"1788.7","value":"1659.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"517"},{"groupId":"OG001","value":"536"},{"groupId":"OG002","value":"544"}],"units":"Participants"}],"title":"Anti-HPV 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1197.8","upperLimit":"1400.3","value":"1295.1"},{"groupId":"OG001","lowerLimit":"1214.9","upperLimit":"1416.3","value":"1311.7"},{"groupId":"OG002","lowerLimit":"1141.7","upperLimit":"1329.5","value":"1232.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"517"},{"groupId":"OG001","value":"536"},{"groupId":"OG002","value":"544"}],"units":"Participants"}],"title":"Anti-HPV 11"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6476.1","upperLimit":"7522.8","value":"6979.8"},{"groupId":"OG001","lowerLimit":"6772.7","upperLimit":"7853.1","value":"7292.9"},{"groupId":"OG002","lowerLimit":"6458.7","upperLimit":"7474.9","value":"6948.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"529"},{"groupId":"OG001","value":"542"},{"groupId":"OG002","value":"556"}],"units":"Participants"}],"title":"Anti-HPV 16"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1970.9","upperLimit":"2353.5","value":"2153.7"},{"groupId":"OG001","lowerLimit":"1955.6","upperLimit":"2329.0","value":"2134.1"},{"groupId":"OG002","lowerLimit":"1804.3","upperLimit":"2143.5","value":"1966.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"531"},{"groupId":"OG001","value":"547"},{"groupId":"OG002","value":"563"}],"units":"Participants"}],"title":"Anti-HPV 18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1738.5","upperLimit":"2058.2","value":"1891.6"},{"groupId":"OG001","lowerLimit":"1719.3","upperLimit":"2029.1","value":"1867.8"},{"groupId":"OG002","lowerLimit":"1731.0","upperLimit":"2039.6","value":"1879.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"522"},{"groupId":"OG001","value":"542"},{"groupId":"OG002","value":"553"}],"units":"Participants"}],"title":"Anti-HPV 31"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"909.2","upperLimit":"1057.2","value":"980.4"},{"groupId":"OG001","lowerLimit":"856.2","upperLimit":"994.4","value":"922.7"},{"groupId":"OG002","lowerLimit":"865.0","upperLimit":"1002.3","value":"931.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"534"},{"groupId":"OG001","value":"543"},{"groupId":"OG002","value":"560"}],"units":"Participants"}],"title":"Anti-HPV 33"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"650.1","upperLimit":"785.0","value":"714.4"},{"groupId":"OG001","lowerLimit":"754.1","upperLimit":"908.5","value":"827.7"},{"groupId":"OG002","lowerLimit":"619.0","upperLimit":"743.6","value":"678.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"534"},{"groupId":"OG001","value":"548"},{"groupId":"OG002","value":"565"}],"units":"Participants"}],"title":"Anti-HPV 45"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"860.8","upperLimit":"1011.0","value":"932.9"},{"groupId":"OG001","lowerLimit":"931.0","upperLimit":"1091.2","value":"1007.9"},{"groupId":"OG002","lowerLimit":"898.1","upperLimit":"1050.3","value":"971.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"533"},{"groupId":"OG001","value":"547"},{"groupId":"OG002","value":"562"}],"units":"Participants"}],"title":"Anti-HPV 52"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1190.0","upperLimit":"1391.3","value":"1286.7"},{"groupId":"OG001","lowerLimit":"1244.6","upperLimit":"1453.3","value":"1344.9"},{"groupId":"OG002","lowerLimit":"1119.6","upperLimit":"1303.6","value":"1208.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"531"},{"groupId":"OG001","value":"539"},{"groupId":"OG002","value":"560"}],"units":"Participants"}],"title":"Anti-HPV 58"}],"denoms":[{"counts":[{"groupId":"OG000","value":"535"},{"groupId":"OG001","value":"549"},{"groupId":"OG002","value":"565"}],"units":"Participants"}],"description":"Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. Titers were reported in milli Merck Units/mL.","dispersionType":"95% Confidence Interval","groups":[{"description":"9-valent human papillomavirus (9vHPV) L1 virus-like particle (VLP) vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.","id":"OG000","title":"Base Study: 9- to 15-Year-Old Females (Lot 1)"},{"description":"9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 2.","id":"OG001","title":"Base Study: 9- to 15-Year-Old Females (Lot 2)"},{"description":"9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 3.","id":"OG002","title":"Base Study: 9- to 15-Year-Old Females (Lot 3)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"9-15-year-old females who received 3 vaccinations from Lots 1, 2, or 3 and met following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range.","reportingStatus":"POSTED","timeFrame":"4 weeks post-vaccination 3 (Month 7)","title":"Base Study: GMTs for Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)","type":"PRIMARY","unitOfMeasure":"milli Merck Units/mL"}